The commonly used pathology technique to assess EGFR mutation status is the biopsy, which is time-consuming and expensive, and its accuracy is affected by tumor heterogeneity [8,9]; moreover, many patients cannot be tested through biopsy due to health conditions and other reasons. Here, EGFR is linked to neoplasm.